Next Article in Journal
New Stable Cu(I) Catalyst Supported on Weakly Acidic Polyacrylate Resin for Green C-N Coupling: Synthesis of N-(Pyridin-4-yl)benzene Amines and N,N-Bis(pyridine-4-yl)benzene Amines
Next Article in Special Issue
Production and Anti-Melanoma Activity of Methoxyisoflavones from the Biotransformation of Genistein by Two Recombinant Escherichia coli Strains
Previous Article in Journal / Special Issue
Inhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1α/VEGF Signaling Pathway
Open AccessArticle

Pharmacological Properties of Riparin IV in Models of Pain and Inflammation

1
Faculdade de Farmácia, Universidade Federal da Bahia, 40170-290 Salvador, BA, Brazil
2
Centro de Pesquisas Gonçalo Moniz, FIOCRUZ, 40296-710 Salvador, BA, Brazil
3
Laboratório de Tecnologia Farmacêutica, Universidade Federal da Paraíba, 58051-900 João Pessoa, PB, Brazil
4
Departamento de Bioquímica e Farmacologia, Universidade Federal do Piauí, 64049-550 Teresina, PI, Brazil
5
Centro de Biotecnologia e Terapia Celular, Hospital São Rafael, 41253-190 Salvador, BA, Brazil
*
Author to whom correspondence should be addressed.
Academic Editor: David J. Newman
Molecules 2016, 21(12), 1757; https://doi.org/10.3390/molecules21121757
Received: 11 November 2016 / Revised: 7 December 2016 / Accepted: 17 December 2016 / Published: 21 December 2016
(This article belongs to the Special Issue Natural Product: A Continuing Source of Novel Drug Leads)
Riparins, natural alkaloids of the alkamide group, can be synthesized by simple methods, enhancing their potential application in pharmaceutical development. Here, the pharmacological properties of riparins were investigated in in vitro and in vivo assays of pain and inflammation in Swiss mice. Inflammatory mediators were measured by radioimmunoassay and Real-Time PCR. Riparins I, II, III and IV (1.56–100 mg/kg; ip) produced dose-related antinociceptive effects in the formalin test, exhibiting ED50 values of 22.93, 114.2, 31.05 and 6.63 mg/kg, respectively. Taking the greater potency as steering parameter, riparin IV was further investigated. Riparin IV did not produce antinociceptive effect on the tail flick, suggesting that its antinociception is not a centrally-mediated action. In fact, riparin IV (1.56–25 mg/kg) produced dose-related antinociceptive and antiedematogenic effects on the complete Freund’s adjuvant (CFA)-induced paw inflammation in mice. During CFA-induced inflammation, riparin IV did not modulate either the production of cytokines, TNF-α and IL-10, or COX-2 mRNA expression. On the other hand, riparin IV decreased the PGE2 levels in the inflamed paw. In in vitro assays, riparin IV did not exhibit suppressive activities in activated macrophages. These results indicate, for the first time, that riparin IV induces antinociceptive and anti-inflammatory effects, possibly through the inhibition of prostanoid production. View Full-Text
Keywords: anti-inflammatory; antinociception; PGE2; cytokines; riparins anti-inflammatory; antinociception; PGE2; cytokines; riparins
Show Figures

Graphical abstract

MDPI and ACS Style

Nascimento, O.A.; Espírito-Santo, R.F.; Opretzka, L.C.F.; Barbosa-Filho, J.M.; Gutierrez, S.J.C.; Villarreal, C.F.; Soares, M.B.P. Pharmacological Properties of Riparin IV in Models of Pain and Inflammation. Molecules 2016, 21, 1757.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop